HCV prevalence and predominant genotype in IV drug users

Publish Year: 1393
نوع سند: مقاله ژورنالی
زبان: English
View: 303

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_RCM-1-4_006

تاریخ نمایه سازی: 2 دی 1398

Abstract:

Hepatitis C virus (HCV) causes 308000 deaths due to liver cancer and 758000 deaths due to cirrhosis every year. Almost 170 million people have HCV infection around the world. Information regarding this virus helps us to determine the prevalence of other hepatitis C genotypes in population, especially in intravenous drug users. It is assumed that some genotypes are more common in certain areas or groups of people. A recent study strongly confirms the central role of injecting network traits, not only as a transmission factor but also as a predictor of HCV genotype and phylogenetic determination in different communities. Hepatitis C genotypes and subtypes have different prevalence considering the country. Risk factors such as transfusion, hemodialysis, root of acquisition and etc, are detected in intravenous drug users. Several conducted studies have investigated the prevalence, risk factors, and predominance of HCV genotypes infection in different parts of Iran.

Keywords:

Genotype , Intravenous drug users (IDUS) , Hepatitis C virus (HCV)

Authors

Asad Andalibalshohada

Department of Infectious and Tropical Disease, Mashhad University of Medical Sciences, Mashhad, Iran

Seyed Abdolrahim Rezaii

Department of Immunology, Mashhad University of Medical Sciences, Mashhad, Iran

Farshid Abedi

Department of Infectious and Tropical Disease, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Mathers C, Fat DM, Organization WH, Boerma JT. The Global ...
  • Longo D, Fauci A, Kasper D, et al. Harrison’s principles ...
  • Zanetti AR. Global surveillance and control of hepatitis C. Report ...
  • Choo Q-L, Kuo G, Weiner AJ, et al. Isolation of ...
  • Lindenbach B, Rice C. Flaviviridae: the viruses and their replication. ...
  • Te HS, Jensen DM. Epidemiology of hepatitis B and C ...
  • Dore GJ, Freeman AJ, Law M, et al. Is severe ...
  • Limburg W. Natural history, treatment and prevention of hepatitis C ...
  • Verna EC, Brown RS Jr. Hepatitis C virus and liver ...
  • Samimi-Rad K, Toosi MN, Masoudi-nejad A, et al. Molecular epidemiology ...
  • Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, et al. HIV, hepatitis ...
  • Imani R, Karimi A, Rouzbahani R, et al. Seroprevalence of ...
  • Holmes E. Sequence variability in the 5’non-coding region of hepatitis ...
  • Lindebach B, Rice C. The hepatitis C viruses. In: Knipe ...
  • Woodfield DG, Harness M, Rix-Trott K, et al. Identification and ...
  • Harris KA, Gilham C, Mortimer PP, et al. The most ...
  • Freeman AJ, Zekry A, Whybin LR, et al. Hepatitis C ...
  • Zein NN. Clinical significance of hepatitis C virus genotypes. Clin ...
  • Krekulova L, Rehak V, Madrigal N, et al. Genotypic and ...
  • Chlabicz S, Flisiak R, Kowalczuk O, et al. High prevalence ...
  • Aitken CK, McCaw RF, Bowden DS, et al. Molecular epidemiology ...
  • Brewer DD, Hagan H, Sullivan DG, et al. Social structural ...
  • Pilon R, Leonard L, Kim J, et al. Transmission patterns ...
  • Sacks-Davis R, Daraganova G, Aitken C, et al. Hepatitis C ...
  • De P, Cox J, Boivin JF, et al. The importance ...
  • Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology ...
  • Rezvan H, Abolghassemi H, Kafiabad SA. Transfusion-transmitted infections among multitransfused ...
  • Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology ...
  • Zamani S, Radfar R, Nematollahi P, et al. Prevalence of ...
  • Kheirandish P, SeyedAlinaghi S, Jahani M, et al. Prevalence and ...
  • Zamani S, Ichikawa S, Nassirimanesh B, et al. Prevalence and ...
  • Mohammad Alizadeh AH, Alavian SM, Jafari K, et al. Prevalence ...
  • Mohtasham Amiri Z, Rezvani M, Jafari Shakib R, et al. ...
  • Rahbar AR, Rooholamini S, Khoshnood K. Prevalence of HIV infection ...
  • Khani M, Vakili M. Prevalence and risk factors of HIV, ...
  • Asgari F, Gouya M, Fotouhi K, et al. Hepatitis C ...
  • Zali M, Nowroozi A, Amir-rasooly H, et al. Prevalence of ...
  • Micalessi MI, Gerard C, Ameye L, et al. Distribution of ...
  • Dal Molin G, Ansaldi F, Biagi C, et al. Changing ...
  • Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients ...
  • Hosseini-Moghaddam SM, Keyvani H, Kasiri H, et al. Distribution of ...
  • Alavian SM, Miri SM, Keshvari M, et al. Distribution of ...
  • Assarehzadegan MA, Shakerinejad G, Noroozkohnejad R, et al. Prevalence of ...
  • Keyvani H, Alizadeh AH, Alavian SM, et al. Distribution frequency ...
  • Kabir A, Alavian SM, Keyvani H. Distribution of hepatitis C ...
  • Mousavi SF, Moosavy SH, Alavian SM, et al. Distribution of ...
  • Joukar F, Khalesi AK, Jafarshad R, et al. Distribution of ...
  • Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors ...
  • Ghavanini AA, Sabri MR. Hepatitis B surface antigen and anti-hepatitis ...
  • Abedi F, Madani H, Asadi A, et al. Significance of ...
  • Zali M-R, Aghazadeh R, Nowroozi A, et al. Anti-HCV antibody ...
  • Alavian S-M, Adibi P, Zali M-R. Hepatitis C virus in ...
  • Hellard ME, Hocking JS, Crofts N. The prevalence and the ...
  • Samuel MC, Doherty PM, Bulterys M, et al. Association between ...
  • World Health Organization. Hepatitis C-Revised October 2000. Geneva; 2000 [Accessed ...
  • Rehman L, Ullah I, Ali I, et al. Active hepatitis ...
  • Lopes CL, Teles SA, Espirito-Santo MP, et al. Prevalence, risk ...
  • Xia X, Luo J, Bai J, et al. Epidemiology of ...
  • Judd A, Hutchinson S, Wadd S, et al. Prevalence of, ...
  • Vicknasingam B, Narayanan S, Navaratnam V. Prevalence rates and risk ...
  • Paintsil E, Verevochkin SV, Dukhovlinova E, et al. Hepatitis C ...
  • Muasya T, Lore W, Yano K, et al. Prevalence of ...
  • Liu JY, Lin HH, Liu YC, et al. Extremely high ...
  • Shrestha SM, Shrestha S, Tsuda F, et al. Infection with ...
  • Aspinall EJ, Weir A, Sacks-Davis R, et al. Does informing ...
  • Amin J, Law MG, Bartlett M, et al. Causes of ...
  • Gibson A, Randall D, Degenhardt L. The increasing mortality burden ...
  • Swan T. The hepatitis C treatment pipeline report. Treatment action ...
  • Palmateer N, Kimber J, Hickman M, et al. Evidence for ...
  • نمایش کامل مراجع